Seplat's Q1 Boom Contrasts with Tech Sector Struggles in LSE Pre-Market

📈 Today's Key Themes

Pre-market announcements paint a picture of contrasting fortunes across sectors on the London Stock Exchange. The energy sector shines with Seplat Energy (#SEPL) reporting exceptional Q1 results, while technology and healthcare firms face headwinds. Consulting and professional services show resilience, with Elixirr International (#ELIX) posting strong annual results. However, NHS restructuring and market challenges are impacting several healthcare companies, highlighting the divergent paths different sectors are taking in the current economic landscape.

💡 Company Updates

Quarterly Updates

Seplat Energy (#SEPL) has delivered a standout Q1 2025 performance, with production soaring 167% year-on-year to 131,561 boepd. Revenue surged by an impressive 350% to $809.3 million, while Adjusted EBITDA grew 224.9% to $400.6 million. The company's strong cash flow allowed it to reduce gross debt by 21% through early repayment of a $250 million revolving credit facility. With a cash balance of $334.6 million at quarter-end, Seplat's financial position appears robust, supporting a very positive sentiment for the stock.

Annual Results

Elixirr International (#ELIX) reported strong annual results for FY24, with revenue up 30% to £111.3 million, including 13% organic growth. Adjusted profit before tax increased by 22% to £29.7 million, and free cash flow surged 74% to £28.1 million. The US market now accounts for 55% of revenue, underlining the company's successful diversification strategy. Despite a slight dip in EBITDA margin to 28.0%, the overall performance and positive outlook support a good sentiment for Elixirr's stock. In contrast, Science in Sport (#SIS) faced challenges in FY24, with revenue declining 17.2% to £51.9m. However, the company managed to double its Underlying EBITDA to £4.2m and improve its gross margin to 45.3%. Despite these improvements, the significant revenue drop and ongoing operational losses paint a challenging picture, warranting a cautious outlook.

Trading Updates

Feedback plc (#FDBK) issued a concerning trading update, projecting a 23.7% year-on-year revenue decline to approximately £0.9m. The company attributes this to increased uncertainty and delays in contract awards due to NHS restructuring. While Feedback remains well-funded with £6.6m in cash and short-term investments, the high valuation multiple of around 8.5x revenue suggests potential downside risk.

🎯 Leading Developments

Strategic Contracts and Partnerships

Pulsar Group (#PULS) has secured a major contract expansion with one of the world's largest advertising and marketing services groups. This strategic win increases Pulsar's annual recurring revenue from the customer by over 150% to US$2.2 million, with the total contract value expected to reach US$6.6 million over the agreement's duration. Pulsar's platform will replace multiple incumbent competitor products across the customer's global portfolio, signaling strong market validation and potential for future growth.

"This strategic partnership reinforces Pulsar's position as a trusted provider in the global marketing and advertising technology landscape."

Corporate Actions

MaxCyte (#MXCT) has filed a definitive proxy statement to seek shareholder approval for the cancellation of its shares from trading on the AIM market. The last day of trading on AIM is expected to be June 25, 2025, with the delisting effective June 26, 2025. This move could potentially impact liquidity for UK investors and may lead to some short-term selling pressure as AIM-focused funds adjust their holdings.

Operational Challenges

CyanConnode (#CYAN) issued a trading update revealing significant delays in shipments, particularly in India. The company now expects FY25 revenue to be approximately £14 million, resulting in an EBITDA loss. The delays are attributed to local and national elections in India and consumer resistance to prepaid smart metering models. While CyanConnode's contracted outstanding order book has grown from £50 million to £180 million, the near-term operational challenges may weigh on investor sentiment. Read more

📅 Week Ahead

29 April 2025: AstraZeneca PLC (#AZN) Q1 2025 results announcement
29 April 2025: BP p.l.c. (#BP.) to publish 1Q25 results
29 April 2025: Coca-Cola Europacific Partners PLC (#CCEP) Q1 2025 Trading Update Release
30 April 2025: Lloyds Banking Group plc (#LLOY) Q1 2025 Trading Update
30 April 2025: Haleon plc (#HLN) Q1 2025 Trading Statement

View full calendar

Market Summary